Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INVEGA TRINZA vs ARISTOCORT A
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Paliperidone is the major active metabolite of risperidone. It is a benzisoxazole derivative antipsychotic that antagonizes central dopamine type 2 (D2) and serotonin type 2 (5-HT2A) receptors. It also antagonizes alpha-1 and alpha-2 adrenergic, and histamine H1 receptors.
Triamcinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, suppress cytokine production, and decrease inflammation and immune responses.
Schizophrenia (FDA-approved maintenance treatment in patients adequately treated with once-monthly paliperidone palmitate for at least 4 months)
Inflammatory dermatoses (e.g., eczema, psoriasis, contact dermatitis),Allergic dermatitis,Lichen planus,Discoid lupus erythematosus,Pruritus,Off-label: Oral lichen planus, keloids (intralesional injection)
Administered intramuscularly (gluteal or deltoid) at 3-month intervals. Starting dose: 350 mg, 525 mg, or 700 mg based on prior stabilization dose of oral paliperidone or INVEGA SUSTENNA. Maximum dose: 700 mg.
Intralesional injection: 2.5-5 mg per lesion, repeated every 1-2 weeks. Topical: Apply thin film to affected area 2-4 times daily.
Terminal elimination half-life: 3 to 6 months (mean 118 days) due to slow dissolution from intramuscular depot; clinical context: steady state reached after 3 injections every 3 months.
Terminal half-life: 2-3 hours for triamcinolone acetonide. Clinical context: Duration of action longer due to receptor binding and intracellular activity; anti-inflammatory effects persist 24-48 hours after IM administration.
Contraindicated in e GFR <15 m L/min/1.73m². For e GFR 15-29 m L/min/1.73m²: 350 mg initially, then 350 mg every 3 months. For e GFR 30-49 m L/min/1.73m²: 350 mg initially, then 350 mg every 3 months. For e GFR ≥50 m L/min/1.73m²: no adjustment.
No dose adjustment required for renal impairment.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA TRINZA is not approved for use in patients with dementia-related psychosis.
INVEGA TRINZA (paliperidone palmitate) is a Pregnancy Category C drug. First trimester: Limited human data; animal studies show increased fetal resorptions and skeletal delays at high doses. Second and third trimesters: Risk for extrapyramidal and withdrawal symptoms in neonates after in utero exposure (e.g., agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress). Antipsychotic use near term may increase risk for neonatal extrapyramidal symptoms. Overall, risk-benefit analysis required.
FDA Pregnancy Category C. First trimester: Corticosteroids are associated with an increased risk of cleft palate and intrauterine growth restriction. Second and third trimesters: May cause fetal adrenal suppression and reduced placental weight. Chronic maternal use may lead to premature birth and low birth weight.
INVEGA TRINZA is a long-acting injectable paliperidone palmitate formulation administered every 3 months. It requires 2 loading doses of the monthly formulation (INVEGA SUSTENNA) prior to initiation. The dose should be adjusted based on renal function, and it is contraindicated in patients with severe renal impairment (e GFR < 15 m L/min/1.73m2). Administer only intramuscularly into the deltoid or gluteal muscle; do not administer intravenously or subcutaneously. Use with caution in patients with known risk factors for QT prolongation, significant leukocyte/neutrophil count abnormalities, or a history of neuroleptic malignant syndrome. Monitor for orthostatic hypotension, especially during dose titration.
ARISTOCORT A (triamcinolone acetonide) is a potent topical corticosteroid. Avoid prolonged use on face, groin, or axillae due to risk of atrophy. Use no more than 2 weeks continuously. Do not use with occlusive dressings unless directed. Monitor for adrenal suppression if used over large areas (>20% BSA).
No interactions on record
No interactions on record
Common clinical questions about INVEGA TRINZA vs ARISTOCORT A, answered by our medical review team.
INVEGA TRINZA is a Atypical Antipsychotic that works by Paliperidone is the major active metabolite of risperidone. It is a benzisoxazole derivative antipsychotic that antagonizes central dopamine type 2 (D2) and serotonin type 2 (5-HT2A) receptors. It also antagonizes alpha-1 and alpha-2 adrenergic, and histamine H1 receptors.. ARISTOCORT A is a Corticosteroid that works by Triamcinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, suppress cytokine production, and decrease inflammation and immune responses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INVEGA TRINZA and ARISTOCORT A depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INVEGA TRINZA is: Administered intramuscularly (gluteal or deltoid) at 3-month intervals. Starting dose: 350 mg, 525 mg, or 700 mg based on prior stabilization dose of oral paliperidone or INVEGA SUSTENNA. Maximum dose: 700 mg.. The standard adult dose of ARISTOCORT A is: Intralesional injection: 2.5-5 mg per lesion, repeated every 1-2 weeks. Topical: Apply thin film to affected area 2-4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INVEGA TRINZA and ARISTOCORT A in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INVEGA TRINZA is classified as Category C. INVEGA TRINZA (paliperidone palmitate) is a Pregnancy Category C drug. First trimester: Limited human data; animal studies show increased fetal resorptions and skeletal delays at h. ARISTOCORT A is classified as Category C. FDA Pregnancy Category C. First trimester: Corticosteroids are associated with an increased risk of cleft palate and intrauterine growth restriction. Second and third trimesters: M. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Paliperidone is predominantly metabolized by dealkylation, hydroxylation, and dehydrogenation, with minor contribution from CYP2D6 and CYP3A4. It is also a substrate of P-glycoprotein (P-gp).
Triamcinolone acetonide is primarily metabolized in the liver via CYP3A4, with minor metabolism by other CYP enzymes. Metabolites are inactive.
Renal: 59-80% as unchanged drug and metabolites; fecal: 6-15%; biliary: minimal.
Renal: 75% as metabolites (primarily conjugated), 15% as unchanged drug. Biliary/fecal: 10%.
74-84% bound to albumin and alpha-1-acid glycoprotein.
68-78% bound to albumin and corticosteroid-binding globulin (CBG).
Vd: 2-4 L/kg (extensive tissue distribution); clinical meaning: high Vd indicates extensive peripheral binding, supporting long duration.
Vd: 0.8-1.2 L/kg. Clinical meaning: Indicates extensive tissue distribution, including synovial fluid and skin.
Intramuscular: 100% (absolute bioavailability after injection).
Intramuscular: 100% (depot preparation). Topical: 0.5-1% systemically absorbed from intact skin; higher with occlusion or inflamed skin. Oral: Not applicable (not available orally in this formulation).
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A and B). Not studied in severe impairment (Child-Pugh Class C).
No specific Child-Pugh based guidelines; use with caution in severe hepatic impairment.
Not approved for use in pediatric patients. Safety and efficacy not established in patients <18 years.
Topical: Apply sparingly to affected area 1-2 times daily; limit duration and use lowest potency. Intralesional: Not recommended for children.
No specific dose adjustment recommended, but elderly patients may have reduced renal function; assess renal function (e GFR) and adjust accordingly. Use lowest effective dose and monitor for orthostatic hypotension, sedation, and extrapyramidal symptoms.
Use lowest effective dose for shortest duration due to increased risk of skin atrophy and systemic effects.
No FDA black box warning.
Avoid grapefruit juice as it may increase paliperidone levels. No significant food interactions otherwise. Advise moderation of alcohol as it may exacerbate CNS depression.
No known food interactions for topical triamcinolone acetonide. Oral triamcinolone may be taken with food to reduce GI upset.
Paliperidone is excreted in human breast milk; M/P ratio not established. The relative infant dose is estimated at 2.8-5.1% of maternal weight-adjusted dose. Monitor infant for sedation, irritability, poor feeding, and extrapyramidal signs. Consider benefits of breastfeeding and need for maternal therapy.
Small amounts of triamcinolone acetonide are excreted in human milk. M/P ratio not established. Potential for adrenal suppression in the infant, especially with high maternal doses. The risk to the breastfed infant is considered low with short-term, low-to-moderate doses.
No established dosing adjustment guidelines for INVEGA TRINZA during pregnancy. Pregnancy may alter pharmacokinetics (e.g., increased clearance, volume of distribution), potentially requiring dose adjustments. Monitor clinical response and tolerability; consider more frequent dosing intervals or dose titration. Use lowest effective dose. Postpartum, return to pre-pregnancy dose as pharmacokinetics normalize.
No specific dose adjustments recommended for triamcinolone acetonide in pregnancy. However, pregnancy may alter corticosteroid pharmacokinetics (e.g., increased clearance), but clinical significance is unclear. Use the lowest effective dose for the shortest duration.
This medication is given as an injection once every 3 months by a healthcare professional.,Do not attempt to self-administer; it must be given by a doctor or nurse.,You must first receive two doses of the monthly injection (Invega Sustenna) before starting this medication.,Common side effects include injection site pain, sleepiness, dizziness, weight gain, and increased prolactin levels.,Avoid alcohol and grapefruit juice as they may increase side effects.,Seek emergency medical attention if you experience severe muscle stiffness, fever, confusion, or irregular heartbeat.,Inform your doctor if you are pregnant, breastfeeding, or planning to become pregnant.,Do not drive or operate heavy machinery until you know how this medication affects you.
Apply a thin layer to affected skin only, avoiding healthy skin.,Do not cover with bandages or wraps unless instructed by your doctor.,Wash hands after application unless treating hands.,Do not use on broken skin, infections, or near eyes/mouth.,Stop use and contact doctor if irritation occurs or no improvement after 2 weeks.